Two innovative Alzheimer’s drugs, donanemab and lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending independent living, by…… Donanemab and Lecanemab rejected for the NHS...
The UK Government’s Spending Review, announced on June 11, 2025, by Chancellor Rachel Reeves, outlined spending and investment plans through 2029-30, addressing key public service priorities amidst a challenging fiscal environment. While the review did…… 2025 Government Spending Review...
Alzheimer’s disease is often seen as a brain problem, but new evidence shows it can affect other body parts too. Scientists at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute at…… Secondary dementia problems...